PA-PPG
8.8.2016 14:12:52 CEST | Business Wire | Press release
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Soborg, Denmark, that helped to revitalize and add shelter and seating to the parkour area of the City’s Arena, an outdoor activity space adjacent to the Hoje Gladsaxe housing project. The Colorful Communities program provides PPG employees and products along with financial contributions to bring color and vitality to communities where our company operates around the world. The program increases PPG’s commitment to invest in communities by adding $10 million to support efforts made during a 10-year period.
The project brought together more than 30 volunteers who are employees at PPG’s nearby architectural coatings, automotive refinish, and protective and marine coatings operations in Soborg to spend two days revitalizing the parkour area. PPG provided more than $18,500 for the project, as well as about 150 liters of DYRUP® Façade Extra paint products in 10 colors.
Young residents who use the City's Arena (Byens Arena) – an outdoor area that encourages movement, activity and play, mostly for residents of the adjacent 2,500-unit Hoje Gladsaxe housing project – expressed a desire for development and beautification of the parkour area. There was a need to make the area more welcoming in the hope of inviting more use. Large concrete features were installed to provide shelter and accommodation for visitors, and artist Anders Benmouyal facilitated a workshop where PPG employees and Hoje Gladsaxe residents came together and decorated the new concrete features.
“From the beginning, we were sure that revitalizing an area of Hoje Gladsaxe was right for this project – the residents are so close to our site, they are actually our neighbors,” said Peter Soerensen, PPG general manager, architectural coatings, Denmark. “We hope this is the beginning of close cooperation on more community initiatives. Already we are planning an educational day at our PPG site for local school students.”
The Colorful Communities program is PPG’s signature initiative for community engagement efforts, with the aim to protect and beautify the neighborhoods where PPG operates around the world. Together with community partners and PPG employees who volunteer, the program supports projects that transform community assets using donated PPG products. In 2015, PPG completed 11 Colorful Communities projects, and it expects to complete about 30 more this year.
PPG and the PPG Foundation aim to bring color and brightness to PPG communities around the world. We donated more than $7.8 million in 2015 to hundreds of community organizations across 20 countries. By investing in educational opportunities, we help grow today’s skilled workforce and develop tomorrow’s innovators in industries related to coatings and specialty materials. Plus, we empower PPG employees to make an impact for causes that are important to them by supporting their volunteer efforts and charitable giving. Learn more at www.ppgcommunities.com and follow @PPG_Communities on Twitter.
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for more than 130 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.3 billion in 2015. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .
We protect and beautify the world and Colorful Communities are trademarks and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.
Dyrup is a registered trademark of Dyrup A/S.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160808005028/en/
Contact:
PPG Media:
Mark Silvey, +1 412-434-3046
Corporate
Communications
silvey@ppg.com
www.ppgcommunities.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
